Chronic Lymphocytic Leukemia Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Why should you consider a clinical trial if you are a CLL patient?
Deborah Sims is a young chronic lymphocytic leukaemia (CLL) patient, undertaking a clinical trial of obinutuzumab and venetoclax (ABT-199). Here, Deborah talks about why she believes that everyone sho... Author: PatientPowerEU Added: 04/11/2016 (Source: Oncology Tube)
Source: Oncology Tube - April 11, 2016 Category: Cancer & Oncology Source Type: podcasts

Venetoclax dose-escalation and obinutuzumab treatment schedule in a clinical trial
Deborah Sims is a young chronic lymphocytic leukaemia (CLL) patient, undertaking a clinical trial of obinutuzumab and venetoclax (ABT-199). Here, Deborah describes the dose-escalation regime of veneto... Author: PatientPowerEU Added: 04/11/2016 (Source: Oncology Tube)
Source: Oncology Tube - April 11, 2016 Category: Cancer & Oncology Source Type: podcasts

Prof. John Gribben describes Deborah's clinical trial: venetoclax (ABT-199) plus obinutuzumab
Prof. John Gribben, from the Barts Cancer Institute, London, UK talks about Deborah Sims' clinical trial of obinutuzumab plus venetoclax (ABT-199). Deborah is a chronic lymphocytic leukaemia (CLL) pat... Author: PatientPowerEU Added: 04/11/2016 (Source: Oncology Tube)
Source: Oncology Tube - April 11, 2016 Category: Cancer & Oncology Source Type: podcasts

When FCR is not enough: the story behind Deborah's CLL treatment choices
Prof. John Gribben, from the Barts Cancer Institute, London, UK talks about Deborah Sims, a chronic lymphocytic leukaemia (CLL) patient, diagnosed at the age of 38. This is considered to be young for ... Author: PatientPowerEU Added: 04/11/2016 (Source: Oncology Tube)
Source: Oncology Tube - April 11, 2016 Category: Cancer & Oncology Source Type: podcasts

Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY gives a brief overview of relapsed/refractory chronic lymphocytic leukemia (CLL) and describes the results of a P... Author: PatientPowerEU Added: 03/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 21, 2016 Category: Cancer & Oncology Source Type: podcasts

iwCLL 2017 | International Workshop on Chronic Lymphocytic Leukaemia
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses the upcoming International Wor... Author: VJHemOnc Added: 03/11/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 11, 2016 Category: Cancer & Oncology Source Type: podcasts

Achieving a definitive treatment for chronic lymphocytic leukemia
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses the rapidly changing treatment... Author: VJHemOnc Added: 03/11/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 11, 2016 Category: Cancer & Oncology Source Type: podcasts

Targeting B-cell receptor signaling in lymphoid malignancies
Wyndham Wilson, MD, PhD from the National Cancer Institute, Bethesda, MD talks about the new developments in the fields of chronic lymphocytic leukemia (CLL), mantle cell lymphoma and large B-cell lym... Author: VJHemOnc Added: 03/01/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 1, 2016 Category: Cancer & Oncology Source Type: podcasts

The side-effects profile of novel drugs in chronic lymphocytic leukemia
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX discusses the side-effects profile of novel drugs in chronic lymphocytic leukemia (CLL), presented at the Am... Author: VJHemOnc Added: 02/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 26, 2016 Category: Cancer & Oncology Source Type: podcasts

Importance of prognostic factors in the treatment of CLL and how to assess them
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about the importance of prognostic factors in the treatment of chronic lymphocytic leukemia (CLL). The... Author: VJHemOnc Added: 02/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 26, 2016 Category: Cancer & Oncology Source Type: podcasts

Advances in the treatment of chronic lymphocytic leukemia
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about recent advances in the treatment of chronic lymphocytic leukemia (CLL), presented at the America... Author: VJHemOnc Added: 02/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 26, 2016 Category: Cancer & Oncology Source Type: podcasts

Round table with Prof. John Gribben and Prof. Stephan Stilgenbauer on CLL
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss several topics related to chronic lymphocytic leukemia (CLL). The topics cov... Author: VJHemOnc Added: 02/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 26, 2016 Category: Cancer & Oncology Source Type: podcasts

Overview of Bruton's tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia
Simon Rule, MD from Derriford Hospital, Plymouth, UK provides an overview of Bruton's tyrosine kinase inhibitors (BTK) in chronic lymphocytic leukemia, presented at the American Society of Hematology ... Author: VJHemOnc Added: 02/12/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2016 Category: Cancer & Oncology Source Type: podcasts

Side-effect of idelalisib and its use in chronic lymphocytic leukemia
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY discusses common side-effects observed in the Phase III clinical trial of idelalisib plus bendamustine and rituxi... Author: VJHemOnc Added: 02/11/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 11, 2016 Category: Cancer & Oncology Source Type: podcasts

ASH Clinical News: New Approaches in CLL and Prolymphocytic Leukemia
John Gribben, MD, MSc, talks to ASH Clinical News at the 57th ASH Annual Meeting about the “shocking” speed at which therapeutic options are expanding for patients with chronic lymphocytic leukemia – ... Author: ash Added: 02/02/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 2, 2016 Category: Cancer & Oncology Source Type: podcasts